(Q50146780)

25 February 2018

title

Five un-easy pieces of pharmaceutical policy reform. (English)

1 reference

25 February 2018

1 reference

Marc A Rodwin

1

1 reference

25 February 2018

publication date

1 January 2013

1 reference

25 February 2018

Journal of Law, Medicine, and Ethics

published in

1 reference

25 February 2018

volume

41

1 reference

25 February 2018

issue

3

1 reference

25 February 2018

page(s)

581-589

1 reference

25 February 2018

Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Drug repositioning: identifying and developing new uses for existing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Understanding pharmaceutical research manipulation in the context of accounting manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Uneasy alliance--clinical investigators and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Patient data: property, privacy & the public interest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Rooting out institutional corruption to manage inappropriate off-label drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Registering clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Issues in the registration of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Clinical trial data as a public good

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Thick prescriptions: toward an interpretation of pharmaceutical sales practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

The accuracy of drug information from pharmaceutical sales representatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Narrative review: the promotion of gabapentin: an analysis of internal industry documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Reforming pharmaceutical industry-physician financial relationships: lessons from the United States, France, and Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Physicians under the influence: social psychology and industry marketing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

Financial ties between DSM-IV panel members and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12067

21 January 2018

Identifiers

DOI

10.1111/JLME.12067

1 reference

25 February 2018

1 reference

25 February 2018